PROCEPT BioRobotics Corporation (PRCT)
$18.40+2.79%Close
SELLRECOVERY · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.0B
- Beta
- 0.90
- P/E (TTM)
- -9.03
- Short % float
- 13.60%
- Days to cover
- 5.3
- SI change
- -0.2%
- 1W
- +7.23%
- 1M
- -8.32%
- vs SPY 1W
- +6.07%
- vs SPY 1M
- -11.31%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 12
- VALUE
- 9
- GROWTH
- 42
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-18.4%
REV YoY-
ROE-30.6%
EPS YoY-
ROA-22.9%
GROSS64
OP-34
NET-33
[VALUATION]
P/E TTM-9.03
P/E FWD-
SECTOR PE20.47
INDUSTRY PE22.50
P/B2.91
P/FCF-
EV/EBITDA-8.55
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E22.79
ALTMAN Z-
CURR RATIO6.55
ND/EBITDA-
BETA0.90
Company news
FAQ
- What is LOPJLB’s current signal on PRCT?
- LOPJLB’s latest quantitative signal on PROCEPT BioRobotics Corporation (PRCT) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is PRCT in?
- PROCEPT BioRobotics Corporation (PRCT) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does PROCEPT BioRobotics Corporation (PRCT) do?
- PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to allevi…